Pharmaceuticals News and Research

RSS

Janssen signs license agreement with Vertex to develop, commercialize VX-787 for influenza A treatment

Janssen Pharmaceuticals, Inc.announced today that it has entered into an exclusive license agreement with Vertex Pharmaceuticals for the worldwide development, manufacturing and commercialization of VX-787, a novel medicine in Phase II development for the treatment of influenza A.

18 Jun 2014

First Edition: June 18, 2014

Today's headlines include a report that the cost of health law subsidies may push the measure's overall price tag beyond projections.

18 Jun 2014

New strategy for treating neuroblastoma using modified version of heparin

Researchers at Duke Medicine have identified a new strategy for treating neuroblastoma using a modified version of heparin, a century-old injectable drug that thins the blood to prevent clots from forming.

18 Jun 2014

3SBio signs exclusive license agreement with Selecta Biosciences for pegsiticase

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive license with Selecta Biosciences for pegsiticase (Uricase PEG-20), a pegylated recombinant uricase from candida utilis.

18 Jun 2014

Academy of Nutrition and Dietetics applauds AMA's support for multidisciplinary obesity treatment

The Academy of Nutrition and Dietetics applauds the American Medical Association's recent decision to support increased patient access to evidence-based, multidisciplinary obesity treatment.

18 Jun 2014

FDA accepts Symplmed's Prestalia NDA for hypertension treatment

Symplmed announced today that the U.S. Food and Drug Administration has accepted for review its New Drug Application (NDA) for investigational drug Prestalia, the first single-pill, fixed-dose combination (FDC) of perindopril arginine and amlodipine besylate for the treatment of hypertension in the U.S. Symplmed filed the application under section 505(b)(2) consistent with FDA's guidance.

18 Jun 2014

Compound developed as cholesterol-fighting molecule can kill cancerous cells

Researchers at the University of Missouri have proven that a compound initially developed as a cholesterol-fighting molecule not only halts the progression of breast cancer, but also can kill the cancerous cells.

18 Jun 2014

Eden licenses Sandia’s technology to develop radioactive isotope for medical diagnostic tests

An Albuquerque startup company has licensed a Sandia National Laboratories technology that offers a way to make molybdenum-99, a key radioactive isotope needed for diagnostic imaging in nuclear medicine, in the United States.

18 Jun 2014

Researchers find sharp increase in deaths from commonly prescribed painkillers in US, Canada

The number of deaths involving commonly prescribed painkillers is higher than the number of deaths by overdose from heroin and cocaine combined, according to researchers at McGill University.

18 Jun 2014

Scottsdale Healthcare, TGen initiate AG-120 clinical trial in patients with solid tumors

The Virginia G. Piper Cancer Center at Scottsdale Healthcare and the Translational Genomics Research Institute are studying the safety and effectiveness of a new drug, AG-120, for treatment of patients with solid tumors, especially those with brain tumors and gallbladder bile duct cancer.

18 Jun 2014

BIPI, Lilly announce resubmission of empagliflozin NDA to FDA for treatment of type 2 diabetes

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced the resubmission of a New Drug Application (NDA) for the investigational sodium glucose co-transporter-2 (SGLT2) inhibitor empagliflozin for the treatment of adults with type 2 diabetes (T2D) to the U.S. Food and Drug Administration (FDA).

17 Jun 2014

OHS performs clinical drug trial to reduce cholesterol levels with just one injection

Research One, Inc., an affiliate of Orlando Heart Specialists (OHS), is seeking candidates for a clinical drug trial that could reduce cholesterol levels with just one injection, twice a month.

17 Jun 2014

Alexion announces that FDA grants ODD to Soliris for Myasthenia Gravis treatment

Alexion Pharmaceuticals (Nasdaq:ALXN) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to Soliris® (eculizumab) for the treatment of patients with Myasthenia Gravis (MG), a rare, debilitating neurologic disorder caused by uncontrolled complement activation.

17 Jun 2014

Delphi Genetics announces new license agreement for use of StabyExpress technology in food industry

Delphi Genetics SA has announced today a new license agreement for the use of the StabyExpress® technology in the food industry. The technology will be used for the production of enzymes for food processing.

17 Jun 2014

Medtronic to buy Covidien

Combining the two huge medical device companies will have global implications. Medtronic agreed on Sunday to buy Covidien for $42.9 billion, combining two of the world's biggest medical device makers and helping it reduce its corporate taxes.

17 Jun 2014

Houston clinic finds ways to limit drug industry influence

Doctors are becoming wary of the appearance that drug makers' gifts can influence their prescription choices. Meanwhile, the federal government serves notice that it wants to find a way to preserve a regulation that would allow hospitals to get discounts on orphan drugs.

17 Jun 2014

Provepharm, DFKC partner to launch Methylthioninium chloride Proveblue in Germany

Provepharm, a French company specialized in the development of pharmaceutical applications, and Dr Franz Kohler Chemie, a German leader in the manufacture and supply of organ preservation solutions and antidote pharmaceuticals, today announce that they have entered into a partnership to launch Provepharm’s drug product Methylthioninium chloride Proveblue 5mg/ml solution for injection (the Product) in Germany, for the acute symptomatic treatment of medicinal and chemical products-induced methaemoglobinaemia.

17 Jun 2014

BioClinica announces acquisition of Blueprint Clinical to drive RBM strategies for clinical trials

BioClinica®, Inc., a leading provider of eClinical Solutions for the Pharmaceutical Industry, has announced the acquisition of Blueprint Clinical, a fast-growing company offering ground-breaking technology and extensive expertise to drive successful Risk-Based Monitoring (RBM) strategies for clinical trials.

From Clario 16 Jun 2014

Cumberland acquires assets of Seattle-based Cipe Consulting Group

Cumberland Consulting Group, a national healthcare technology implementation and project management firm, today announced that it has acquired the assets of Seattle-based Cipe Consulting Group, LLC, a growing healthcare technology consulting firm specializing in electronic health records and revenue cycle system implementation and support, including workflow and business analytics.

16 Jun 2014

Arrowhead Research joins with broad-market Russell 3000 Index

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, is set to join the broad-market Russell 3000 Index when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes on June 27, according to a preliminary list of additions posted June 13 on www.russell.com/indexes.

16 Jun 2014

Pharmaceuticals News and Research

Janssen signs license agreement with Vertex to develop, commercialize VX-787 for influenza A treatment

First Edition: June 18, 2014

New strategy for treating neuroblastoma using modified version of heparin

3SBio signs exclusive license agreement with Selecta Biosciences for pegsiticase

Academy of Nutrition and Dietetics applauds AMA's support for multidisciplinary obesity treatment

FDA accepts Symplmed's Prestalia NDA for hypertension treatment

Compound developed as cholesterol-fighting molecule can kill cancerous cells

Eden licenses Sandia’s technology to develop radioactive isotope for medical diagnostic tests

Researchers find sharp increase in deaths from commonly prescribed painkillers in US, Canada

Scottsdale Healthcare, TGen initiate AG-120 clinical trial in patients with solid tumors

BIPI, Lilly announce resubmission of empagliflozin NDA to FDA for treatment of type 2 diabetes

OHS performs clinical drug trial to reduce cholesterol levels with just one injection

Alexion announces that FDA grants ODD to Soliris for Myasthenia Gravis treatment

Delphi Genetics announces new license agreement for use of StabyExpress technology in food industry

Medtronic to buy Covidien

Houston clinic finds ways to limit drug industry influence

Provepharm, DFKC partner to launch Methylthioninium chloride Proveblue in Germany

BioClinica announces acquisition of Blueprint Clinical to drive RBM strategies for clinical trials

Cumberland acquires assets of Seattle-based Cipe Consulting Group

Arrowhead Research joins with broad-market Russell 3000 Index

Free eBook - From lab to market: Accelerate your bioprocessing journey eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Managing vibration in IVF laboratories

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence